Nat105

Manufactured by Roche

The NAT105 is a laboratory instrument designed for nucleic acid testing (NAT). It is a compact, automated system that performs sample preparation, amplification, and detection of target nucleic acid sequences. The NAT105 utilizes real-time PCR technology to provide accurate and reliable results. The specific details and intended uses of this product are not available.

Automatically generated - may contain errors

Lab products found in correlation

E1l3n, by Cell Signaling Technology (2 mentions) Ventana discovery, by Roche (1 mentions) Sp142, by Roche (1 mentions) Sp263, by Roche (1 mentions)

2 protocols using nat105

PD-1 and PD-L1 Immunostaining in Cancer Samples

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

PD-1 and PD-L1 immunostaining of samples from the NKI-AVL cohorts were performed on fresh-cut slides from FFPE blocks using an anti–PD-1 antibody (NAT105, Roche Diagnostics) and anti–PD-L1 antibody (22C3 DAKO, Agilent) on a BenchMark Ultra autostainer Instrument (Ventana Medical Systems) as described previously (7 (link)). PD-L1 immunostaining of samples from the CERTIM cohort was performed using a different anti–PD-L1 antibody (E1L3N, Cell Signaling Technology, catalog No. AB_2687655) on a Bond automat (Leica Biosystems) as described previously by Adam and colleagues (14 (link)).
PD-1 IHC slides were scanned at 20× magnification with a resolution of 0.50 per μm² using an Aperio slide AT2 scanner (Leica Biosystems).

Hummelink K., Tissier R., Bosch L.J., Krijgsman O., van den Heuvel M.M., Theelen W.S., Damotte D., Goldwasser F., Leroy K., Smit E.F., Meijer G.A., Thommen D.S, & Monkhorst K. (2023). A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics. Clinical Cancer Research, 30(4), 814-823.

+ Open protocol

+ Expand

Comprehensive Immune Checkpoint Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemical (IHC) staining was performed using the Ventana Discovery (Ventana Medical System) automated staining system. In brief, slides were incubated at room temperature with the following primary antibodies (dilution, clone, company): anti-PD-L1 (1: 50, E1L3N, Cell Signaling), anti-PD-L1 (RTU, SP263, Roche), anti-PD-L1 (RTU, SP 142, Roche), anti-PD-L1 (1:100, 28.8, Abcam), anti-PD-L2 (1:100, OTI6C3, Acris), anti-PD-1 (RTU, NAT105, Roche), anti-CD8 (RTU, SP57, Roche), anti-CD4 (RTU, SP35, Roche), anti-CD56 (RTU, MRQ-42, Roche), anti-FoxP3 (1:100, 236A/E7, Thermo Fisher) and anti-CTLA4 (1:100, BNI3, Abcam). Expression of PD-L1 and PD-L2 was investigated on tumor and immune cells. CD8, CD4, CD56, FoxP3, CTLA-4, and PD1 staining were used to further characterize the lymphocytes.

Kümpers C., Jokic M., Haase O., Offermann A., Vogel W., Grätz V., Langan E.A., Perner S, & Terheyden P. (2019). Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. Frontiers in Medicine, 6, 27.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!